Key Takeaways
Technology transfer requires more than document exchange; it depends on demonstrated receiving-site capability.
Strong transfer programs preserve process knowledge, development rationale, critical process parameters, and critical quality attributes.
Scale-up tests process understanding and may reveal variables that require control-strategy refinement.
Facility fit, analytical readiness, cross-functional governance, and early gap assessment are central to transfer success.
Sponsors should evaluate CDMOs on transfer readiness, technical depth, life-cycle orientation, and ability to convert development knowledge into manufacturing execution.
Technology Transfer Is No Longer Just a Handoff
Technology transfer has traditionally been treated as a defined project phase that begins once development work is sufficiently mature and a process is ready to move into a new manufacturing environment. Under that view, success depends largely on assembling the correct documents, transferring analytical methods, training the receiving team, and completing a series of engineering or qualification runs. Those activities remain essential, but they do not fully capture what must move from one organization, function, or site to another.
Technology transfer involves the movement of product and process knowledge between development and manufacturing and within or between manufacturing sites. That knowledge forms the basis for the manufacturing process, control strategy, process validation approach, and continual improvement throughout the product life cycle.1
The implication is significant for outsourced development and manufacturing. A sponsor is not simply asking a contract development and manufacturing organization (CDMO) to reproduce a set of instructions. It is asking the partner to understand how the process was developed, determine how it will behave in a different environment, and convert accumulated knowledge into reliable manufacturing execution.
That capability matters at every stage of an outsourced program. Early in development, the receiving organization may need to translate laboratory-scale methods into a process suitable for clinical manufacturing. Later, it may need to increase batch size, adapt the process to different equipment, support process qualification, or move production between sites. In each case, the underlying challenge is the same: preserving the scientific rationale behind the process while adapting execution to a new operational context.
This makes technology transfer a meaningful measure of CDMO value. Capacity, equipment, geographic reach, and cost remain important selection criteria, but none guarantees that a process can move successfully from development into manufacturing or from one facility to another. Transfer performance depends on technical depth, disciplined knowledge management, cross-functional coordination, and the ability to recognize where prior assumptions may no longer hold.
A CDMO that manages these transitions well does more than accept a process. It creates continuity between development and manufacturing, protects the reasoning embedded in the process, and establishes a stronger foundation for scale-up, validation, and continued manufacturing performance.
From Documentation Transfer to Demonstrated Capability
A complete transfer package is necessary, but the existence of documentation does not establish that a process has been transferred successfully. Technology transfer includes both the transfer of documentation and the demonstrated ability of the receiving unit to perform the critical elements of the transferred technology.2 The distinction shifts the focus from information delivery to operational capability.
The sending unit may provide process descriptions, batch records, specifications, analytical methods, development reports, equipment requirements, and historical data. The receiving unit must then interpret that information within its own facility, quality system, equipment configuration, staffing model, and manufacturing procedures. Even detailed instructions may leave important questions unanswered if they do not explain why particular choices were made or which variables have the greatest effect on process performance and product quality.
The receiving team must also distinguish between process elements that should remain fixed and those that may require adaptation. A specific equipment model, mixing configuration, sampling method, or material source may not be available at the new site. Replicating the sending unit’s process exactly may therefore be impossible or inappropriate. The receiving unit must determine whether a proposed alternative preserves the intended process function and remains consistent with the established control strategy.
This work requires active participation from both sides. The sending unit holds knowledge about process history, development decisions, prior failures, and known sensitivities. The receiving unit understands the constraints and capabilities of the new environment. Neither side can complete the transfer independently. The sending unit cannot anticipate every site-specific issue, and the receiving unit cannot interpret every process choice without access to the reasoning behind it.
Transfer readiness should therefore be assessed before formal execution begins. Early discussions should establish the scope of the transfer, the information available, known gaps, responsibilities, acceptance criteria, and the process for resolving technical questions. Waiting until engineering or qualification runs to identify missing knowledge increases the likelihood that issues will emerge when schedules, materials, and manufacturing resources are already committed.
The most effective transfer programs treat demonstrated capability as the objective from the outset. Documentation, training, gap assessments, engineering studies, analytical work, and manufacturing runs should all support the same goal: enabling the receiving organization to execute the process with sufficient understanding and control.
Transferring the Knowledge Behind the Process
A manufacturing procedure records the current version of a process, but it rarely captures the full history that produced it. A robust transfer package must communicate not only what the process is, but how it reached its present form and why its controls were selected.
Relevant information may include process development history, scale-up activities, critical process parameters (CPPs), critical quality attributes (CQAs), pilot- and full-scale development data, deviations, investigations, and change-control history.2 These records reveal the boundaries of current understanding. They show which variables were studied, which conditions produced unacceptable outcomes, where uncertainty remains, and how earlier observations shaped the process.
This context becomes especially important when the receiving unit encounters an unexpected result. A batch record may specify an operating range without explaining whether the range reflects extensive characterization, equipment limitations, or a conservative choice made early in development. A development report may show the selected condition but omit unsuccessful experiments that would help the receiving team understand the risks of moving away from it. Without that history, the receiving unit may repeat earlier work or interpret a familiar process response as a new problem.
The same principle applies to analytical methods. Transferring a method requires more than supplying a procedure and acceptance criteria. The receiving laboratory needs relevant information about method development, sample handling, system suitability, known sources of variability, and the relationship between the method and the control strategy. If an analytical method performs differently at the receiving site, the team must be able to determine whether the difference reflects laboratory execution, equipment, materials, or the behavior of the product itself.
The depth and organization of the knowledge package also influence the efficiency of the transfer. Information scattered across reports, emails, investigations, and individual experience is difficult to use under project pressure. Structured knowledge management allows the receiving team to trace requirements back to development evidence and understand how individual controls relate to product and process risk.
This is one area in which CDMOs can create substantial value before manufacturing begins. An experienced receiving team can evaluate the package critically, identify missing information, distinguish high-priority gaps from lower-risk uncertainties, and convert development knowledge into a transfer plan. That work requires scientific judgment. A passive review may confirm that required documents are present, but it does not establish whether the available knowledge is sufficient to support execution.
The quality of the transfer package also affects future activities. Knowledge captured during development supports the manufacturing process, control strategy, process validation approach, and continual improvement. Incomplete knowledge transfer can therefore create problems beyond the immediate handoff, while a well-constructed package becomes a resource throughout the product life cycle.
Scale-Up and Control Strategy: Where Process Understanding Is Tested
Scale-up is one of the clearest tests of whether a process has been adequately understood. Conditions that appear stable at laboratory or pilot scale may behave differently when equipment size, mixing, heat transfer, mass transfer, hold times, sampling, or processing duration changes. The purpose of scale-up is not simply to increase output. It is to preserve process performance and product quality under a different set of physical and operational conditions.
Process validation follows a life cycle approach that connects process design, process qualification, and continued process verification.3 Development knowledge provides the foundation for those activities, but the knowledge base continues to evolve as the process moves into larger-scale and routine manufacturing environments. Technology transfer, site changes, and scale-up may expose new variables that require further development of the control strategy.4
A strong transfer program anticipates this possibility. It does not assume that the process will behave identically at the receiving site, nor does it treat every difference as evidence that the original process was inadequate. Instead, the team evaluates which process characteristics should remain comparable, which operating parameters may need adjustment, and what evidence will demonstrate that the adapted process remains in control.
For upstream bioprocesses, for example, the receiving team may need to assess how bioreactor configuration and scale affect parameters such as pH, dissolved oxygen, mixing, and process duration, as well as their relationship to product-quality attributes.5 Other processes may require attention to drying behavior, filtration, granulation, blending, filling, or temperature control. The specific variables differ by platform, but the broader principle remains consistent: scale-up requires a mechanistic and empirical understanding of how operating conditions influence quality.
The control strategy provides the bridge between that understanding and manufacturing execution. It translates knowledge about materials, process parameters, equipment, analytical methods, and product attributes into a coordinated set of controls. The receiving organization must understand not only which controls are required, but why they are required and how they interact.
This allows the team to evaluate whether the existing strategy remains appropriate in the new environment. A parameter that was easily controlled at the sending site may require a different monitoring approach at the receiving site. A sampling plan developed for one equipment configuration may not provide equivalent information in another. A material attribute that appeared stable during development may become more important at commercial scale.
Transfer runs should therefore generate knowledge, not merely confirm compliance with predetermined instructions. Observations made during scale-up can refine acceptable ranges, strengthen the rationale for controls, and identify variables that require closer monitoring during qualification or routine manufacture. These refinements should remain connected to the original development knowledge so that adaptations are scientifically justified rather than driven only by operational convenience.
A CDMO’s ability to manage this process reveals the depth of its technical capabilities. Effective scale-up requires more than familiarity with equipment. It requires the ability to connect process behavior, product quality, analytical evidence, and manufacturing controls in a way that supports reliable execution at the intended scale.
Facility Fit, Equipment Fit, and Analytical Readiness
A process cannot be transferred successfully in isolation from the site that will execute it. Facility layout, equipment design, available utilities, material flows, analytical capabilities, and quality procedures all shape how the receiving unit translates process requirements into practice.
Equipment fit is often more complex than comparing stated capacities. Two pieces of equipment may perform the same nominal function while differing in geometry, control capability, shear, mixing pattern, heat transfer, automation, or sampling configuration. Those differences may affect process performance even when the operating setpoints appear comparable. The transfer team must identify where equipment equivalence can be justified and where additional studies or process adjustments are necessary.
Material fit deserves similar attention. Raw materials used during development may not be available from the same supplier, in the same grade, or at the quantities required for larger-scale manufacture. Differences in material attributes, packaging, storage, preparation, or handling can influence process performance. Availability itself may become a constraint if a material was suitable for small development batches but cannot support routine production at the target scale.
Analytical readiness is equally important. The receiving laboratory must have suitable instrumentation, trained personnel, qualified systems, and access to appropriate reference standards and reagents. Method-transfer planning should account for differences in equipment platforms, laboratory practices, and sample logistics. Analytical delays can constrain manufacturing decisions if results are needed to evaluate engineering runs, release materials, or determine whether process changes remain acceptable.
Facility and process-gap assessments provide a structured way to identify these differences before transfer execution. They can examine equipment, utilities, materials, methods, capacity, workflows, and quality-system requirements against the needs of the process (Outsourced Pharma Facility Fit). The objective is not necessarily to eliminate every difference. It is to understand which differences matter, determine how they will be addressed, and establish the evidence needed to support the chosen approach.
A mature receiving organization will also consider interactions among these factors. An equipment change may alter sampling requirements. A new material source may require additional analytical characterization. A facility constraint may affect hold time or sequence of operations. Addressing each issue separately can miss the cumulative effect on the process.
Early gap identification allows the sponsor and CDMO to make informed decisions before manufacturing resources are committed. Some gaps can be closed through equipment modification, procedural changes, training, or targeted development studies. Others may require a different manufacturing approach or a reconsideration of site selection. In either case, early visibility supports more realistic planning and reduces the likelihood that fundamental incompatibilities will surface during qualification or GMP production.
Technology Transfer as a Cross-Functional Partnership
Technology transfer touches too many parts of the product life cycle to reside within a single function. Process development, manufacturing science and technology, operations, analytical development, quality control, quality assurance, engineering, regulatory affairs, supply chain, and project management may all contribute information or make decisions that affect the transfer.
Each group views the process through a different lens. Development teams understand the experimental history and scientific rationale. Manufacturing teams focus on executable instructions, equipment, staffing, and scheduling. Analytical teams evaluate methods and data. Quality teams assess documentation, compliance, deviations, change control, and validation. Regulatory teams consider whether proposed adaptations remain consistent with commitments and filing strategy. Supply-chain teams must ensure that materials, components, and services are available when needed.
Problems arise when these perspectives remain disconnected. A technically reasonable process modification may create a regulatory or validation concern. A material substitution made to address procurement constraints may require analytical comparability work. An engineering solution may affect cleaning, sampling, or environmental controls. Cross-functional review helps identify these consequences before decisions are implemented.
The CDMO–client relationship adds another layer of coordination. Responsibilities must be clearly defined, particularly when development knowledge, manufacturing execution, analytical testing, and quality oversight are distributed across organizations. Ambiguity over who owns a deliverable or decision can slow progress even when the technical issue itself is straightforward.
Effective governance provides a mechanism for resolving such questions. The transfer plan should establish workstreams, decision rights, escalation pathways, deliverables, acceptance criteria, and communication routines. Technical discussions should include the functions needed to evaluate the full consequence of a decision, rather than limiting participation to the group that first identified the issue.
This structure should not turn every question into a lengthy committee process. The purpose of governance is to allow decisions to move efficiently while preserving appropriate technical and quality oversight. Teams need enough context to make informed choices and enough authority to act within defined boundaries.
Communication quality also affects how well tacit knowledge moves between organizations. Not every important observation appears in formal documentation. Experienced development scientists or operators may know that a process is sensitive to a particular sequence, timing variation, visual cue, or handling practice. Structured technical meetings, facility visits, direct observation, and hands-on training can surface knowledge that would otherwise remain with the sending unit.
The strongest outsourcing relationships treat technology transfer as a shared technical program. Both parties remain accountable for identifying gaps, testing assumptions, and building receiving-site capability. That approach creates a more reliable path from development knowledge to manufacturing execution than a transactional exchange of documents and deliverables.
Why Transfer Capability Is a CDMO Differentiator
CDMOs are entrusted with the development and manufacturing of production processes on behalf of pharmaceutical companies, and production platforms and new technologies contribute to differentiation within the sector.6 Technology transfer capability belongs within the same competitive framework because it determines how effectively those assets can be applied to an incoming program.
A facility may have appropriate equipment and available capacity, but the sponsor still needs confidence that the organization can absorb its process, identify gaps, and manage adaptation without losing the connection to product quality. That confidence depends on capabilities that are not always visible in a capacity table or equipment list.
Process-development depth is one indicator. A CDMO with strong development expertise is better positioned to interpret incomplete or evolving processes, evaluate scale-dependent risks, and design studies that close knowledge gaps. Manufacturing experience matters as well, particularly when the receiving site must translate development conditions into operationally robust procedures.
Analytical capability provides another differentiator. The ability to transfer, troubleshoot, and apply methods is essential for assessing raw materials, monitoring the process, evaluating transfer runs, and supporting qualification. Weak analytical readiness can limit the team’s ability to distinguish process variation from measurement variation.
Quality-system maturity also influences transfer performance. Deviations, investigations, change controls, comparability assessments, and validation activities must preserve the relationship between new observations and the existing knowledge base. A system that treats these activities only as documentation requirements may miss opportunities to strengthen process understanding.
Cross-functional coordination brings these capabilities together. Sponsors benefit from a partner that can align development, manufacturing, analytical, quality, engineering, regulatory, and supply-chain perspectives without requiring the sponsor to manage each interface separately. This is particularly valuable when timelines are compressed or when the process remains under active development during transfer.
Transfer performance can therefore serve as an indicator of broader organizational maturity. It reveals whether a CDMO can move beyond executing predefined tasks and assume responsibility for integrating knowledge across the life cycle. That does not make technology transfer the sole criterion for partner selection, but it makes transfer readiness an important part of evaluating whether a CDMO can support a program through scale-up, validation, and sustained manufacturing.
New Modalities Raise the Importance of Transfer Coordination
New modality development illustrates why technology transfer is becoming more strategic. Sponsors working with specialized products may depend on external partners not only for manufacturing capacity but also for regulatory-compliant capabilities, platform technologies, analytical expertise, and experience coordinating activities across organizational boundaries.
Establishing compliant manufacturing capabilities for new treatment modalities can be difficult for pharmaceutical companies to internalize, particularly for start-ups.7 In such cases, the CDMO may contribute knowledge that extends beyond a single manufacturing procedure. The partner may provide platform understanding, equipment expertise, quality systems, analytical strategies, and experience translating a novel process into a controlled manufacturing environment.
Oligonucleotide therapeutics offer another example of development shaped by platform technologies and inter-organizational alliances.8 When multiple organizations contribute materials, process steps, delivery technologies, analytical methods, or specialized manufacturing capabilities, technology transfer becomes a coordination challenge as well as a technical one.
The receiving organization must understand how its work connects to activities performed elsewhere. Material attributes established by one supplier may influence processing at another site. Analytical methods may need to support decisions across several partners. Changes made to improve manufacturability may affect product performance or downstream operations. A transfer plan that focuses only on the boundaries of one facility may overlook dependencies across the broader development network.
Specialized modalities can also place greater weight on platform knowledge. A process may rely on equipment, materials, or analytical approaches that have limited precedent outside a small group of experienced organizations. In these settings, tacit knowledge and prior platform experience may be particularly valuable because the formal process description may not capture every factor that influences performance.
This does not mean that every new modality is inherently more difficult to transfer than a conventional product. Transfer complexity depends on process maturity, platform experience, available knowledge, analytical capability, and the number of organizations involved. The broader lesson is that specialized technologies and distributed development models increase the importance of structured knowledge transfer and clear technical governance.
CDMOs that operate in these areas must be able to integrate product-specific information with platform experience. They need to distinguish between established platform practices and aspects of the process that require product-specific evaluation. That balance helps avoid two opposite errors: treating every incoming program as entirely novel or assuming that platform familiarity eliminates the need for careful transfer.
Building Transfer Readiness Earlier and Selecting the Right Partner
The strongest technology transfers begin before the formal handoff. Because development knowledge provides the foundation for process validation, transfer readiness should be considered while the process is still being designed and characterized.
Early attention to transferability can influence how development data are generated, organized, and interpreted. Teams can document not only selected conditions but also the rationale behind them, the alternatives evaluated, and the limits of current understanding. They can identify materials or equipment that may become difficult to source or reproduce at larger scale. Analytical methods can be developed with future receiving laboratories in mind.
Early CDMO involvement may help expose these issues before the process reaches a stage at which changes become more disruptive. A manufacturing partner can evaluate whether development assumptions remain practical at the intended scale, identify likely facility gaps, and recommend studies that support future qualification. This does not require transferring ownership of development prematurely. It means incorporating manufacturing and transfer considerations while there is still flexibility to address them.
Sponsors evaluating potential partners should therefore look beyond open capacity and nominal technical fit. Relevant questions include whether the CDMO has experience interpreting development history, managing scale-up, transferring analytical methods, assessing equipment and facility gaps, and refining control strategies when new variables emerge. The sponsor should also examine how the organization coordinates its technical, manufacturing, analytical, quality, regulatory, and project-management functions.
The partner’s approach to uncertainty can be revealing. Some processes arrive with extensive development packages, while others contain significant gaps. A transfer-ready CDMO should be able to distinguish information that is essential before execution from questions that can be resolved through planned studies. It should communicate the implications of missing data clearly and propose a proportionate path forward.
Life cycle orientation is equally important. Technology transfer should not end when the first receiving-site batch meets its acceptance criteria. Knowledge generated during engineering, qualification, and routine manufacturing should remain connected to the process history and support continued process verification and improvement. The receiving organization should have systems for capturing new knowledge, evaluating its significance, and incorporating it into process and control documents where appropriate.
Technology transfer is the point at which development knowledge becomes manufacturing capability. For sponsors, successful transfer strengthens confidence that a process can move across scales, sites, and life cycle stages without losing its scientific foundation. For CDMOs, transfer excellence demonstrates the ability to integrate technical understanding, operational execution, quality systems, and cross-functional partnership.
That combination makes technology transfer more than a project milestone. It is a life cycle capability and an increasingly important source of competitive differentiation in outsourced development and manufacturing.
References
“Pharmaceutical Quality System Q10.” International Council for Harmonisation. 4 Jun. 2008.
“WHO Guidelines on Transfer of Technology in Pharmaceutical Manufacturing.” WHO Technical Report Series 961: 285–309 (2011).
“Process Validation: General Principles and Practices.” U.S. Food and Drug Administration. Jan. 2011.
“Q8, Q9, & Q10 Questions and Answers — Appendix: Q&As from Training Sessions (Q8, Q9, & Q10 Points to Consider).” U.S. Food and Drug Administration. 13 Aug. 2012.
Nogal, Nikki. “Technology Transfer for Outsourced Programs: Highlighting Upstream Considerations.” BioProcess International. 23(1–2): 35–40 (2025).
Kurata, Hideyuki, et al. “CDMOs Play a Critical Role in the Biopharmaceutical Ecosystem.” Frontiers in Bioengineering and Biotechnology. 10: 841420 (2022).
Yoshiura, Hiromu, Yayoi Kawata, and Shintaro Sengoku. “Open Innovation and Regulatory Challenges in New Modality Development: The Pivotal Role of Contract Development and Manufacturing Organisations in Advancing Antibody Drugs.” Therapeutic Innovation & Regulatory Science. 59: 63–70 (2025).
Kawata, Yayoi, et al. “Multi-layer Platform Coordination for Open Innovation in Oligonucleotide Therapeutics.” Drug Discovery Today. 30(2): 104288 (2025).
